BioGenes Reports Strong Growth of HCP Assay Development Business
News Feb 28, 2013
BioGenes GmbH announced a strong increase in sales volume in 2012, the year of the company’s 20th anniversary, due to a high demand of specific antibodies and ELISA assays used in drug development processes. In particular, the HCP assay development business showed a remarkable growth increasing by 36% over 2011.
BioGenes is a recognized partner of pharmaceutical companies all over the world. The company has been evaluated by a leading global accounting and auditing firm to be one of the leading companies in HCP assay development.
“Our long-term strategy to focus on HCP assay development pays off and we expect the growth to continue at a similar pace in the months ahead,” said Dagmar Schwertner-Knoll, Marketing Director of BioGenes. “The next milestone is the development of pre-optimized HCP assay kits for more reliable host cell protein detection.”
Antitumor Immune Function in Liver Controlled by Gut MicrobiomeNews
Scientists have found a connection between bacteria in the gut and antitumor immune responses in the liver. The study showed that bacteria found in the gut of mice affect the liver’s antitumor immune function. The findings have implications for understanding the mechanisms that lead to liver cancer and for therapeutic approaches to treat them.READ MORE
You Are What Your Mother EatsNews
While many factors, such as the age of the mother, overall health and genetics ultimately play a role, the correlation between a mother’s nutrition habits and metabolism has been proved to directly impact the growth of her child. And researchers believe they may be one step closer to knowing why.READ MORE
Immune Cells Form Clots in Tumors Aiding Lung Cancer's SpreadNews
Researchers have found that by helping to form clots within tumors, immune cells that flock to a particular type of lung cancer are actually building a foundation for the tumor to spread within the body.READ MORE